CureVac Announces Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Author: Benzinga Newsdesk | April 04, 2024 07:07am

CureVac N.V. (NASDAQ:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced interim data from an ongoing Phase 2 part of the combined Phase 1/2 study of its seasonal influenza vaccine candidate, conducted in collaboration with GSK. The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine candidates with up to eight separate mRNA constructs per candidate. It was designed for broad antigen coverage, encoding antigens matched to all four WHO-recommended flu strains.

Posted In: CVAC GSK